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Abstract
Objective: Patients with primary aldosteronism (PA) have a high prevalence of osteoporosis (OP) and fractures (Fx). 
We evaluated the presence of PA in patients admitted to our metabolic bone disease outpatient clinic.
Design: Study conducted on an in- and outpatient basis in a referral Italian endocrinology unit.
Methods: A total of 2632 patients were evaluated. 2310 were excluded because they were taking drugs known to 
affect bone or mineralocorticoids metabolism or were diagnosed to have a secondary cause of osteoporosis. The 
remaining 322 subjects (304 females, 18 males) took part in the study. Bone mineral density (BMD) and thoracic and 
lumbar spine vertebral morphometry were performed by dual X-ray absorptiometry. All patients were screened for PA 
with aldosterone-to-renin ratio. In those who had positive results, confirmatory tests were performed.
Results: Among 322 subjects, 213 were osteoporotics and 109 were not. PA was diagnosed in eleven out of 213 
osteoporotic patients (5.2%) and one out of 109 non-osteoporotic subjects (0.9%, P = 0.066). PA was observed in 
the 26.1% of patients with the concomitant presence of osteoporosis, hypertension and hypercalciuria. Compared 
with patients without PA, patients with PA had mean values of urinary calcium excretion, 4.8 ± 2.5 mmol/day vs 
7.6 ± 3.2 mmol/day, P < 0.001 and serum PTH levels, 5.4 pmol/L vs 7.3 pmol/L, P < 0.01, significantly higher.
Conclusions: PA should be considered among the causes of secondary OP.
Introduction
Primary aldosteronism (PA) is a disorder of the adrenal 
gland caused by the increased secretion of aldosterone 
that is relatively autonomous of normal regulatory 
mechanism.
Aldosterone excess is associated with hypercalciuria, 
hypocalcemia and subsequent secondary hyperpara­
thyroidism both in rats and in humans (1, 2). In rats, 
these alterations of bone metabolism were associated with 
a decreased bone mass and strength (1) and were rescued 
by the mineralocorticoid receptor antagonist (MRA) 
therapy (3).
In humans, there is evidence that PA patients have 
an increased prevalence of low bone mass and vertebral 
fractures (VFs) and that treatment with adrenalectomy or 
MRA therapy improves the clinical picture (4, 5, 6, 7, 8, 9). 
Moreover, the possible relation between PA and bone was 
suggested by data coming from genomewide association 
studies showing an association between indexes of 
bone strength and some genes involved in aldosterone 
pathways (10). Finally, the presence of mineralocorticoid 
receptors had been demonstrated in osteoblast, osteoclast 
and osteocyte cells (11, 12).
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Recent data showed that a condition of an 
otherwise asymptomatic cortisol excess (i.e. subclinical 
hypercortisolism) is more prevalent than expected in 
patients with osteoporosis (13, 14). Given the negative 
role of the aldosterone excess on bone tissue, we 
hypothesized that in patients with osteoporosis there was 
a high prevalence of PA.
Therefore, the aim of the present study was to 
evaluate the association between osteoporosis and PA and 
as secondary end­point, the prevalence of PA in patients 
with osteoporosis consecutively recruited among the 
subjects referred to our outpatient clinic for metabolic 
bone disease.
Subjects and methods
Study design
The study was carried out at the ‘IRCCS, Casa Sollievo 
della Sofferenza’, San Giovanni Rotondo, Foggia, Italy, 
from November 2012 to May 2015. We evaluated 2632 
consecutive patients referred to our outpatient clinic for 
metabolic bone disease.
Exclusion criteria were use of drugs (bisphosphonates, 
denosumab, teriparatide, raloxifene, bazedoxifene, 
corticosteroids) or diseases (hypogonadism, 
hypercortisolism, primary hyperparathyroidism and 
thyrotoxicosis, bowel diseases, chronic kidney and hepatic 
disease, alcoholism, eating disorders, rheumatologic, 
hematological diseases or oncologic diseases) (15), 
apart from hypercalciuria, known to affect bone or 
mineralocorticoids metabolism. Moreover, hypertensive 
patients have been recruited after their antihypertensive 
therapy had been stopped and/or shifted to not interfering 
antihypertensive medications according to the Endocrine 
Society Guidelines (16).
According to these exclusion criteria, 2310 were 
excluded while 322 subjects were included in the study 
(Fig.  1). All subjects included in the study underwent 
to a dual X­ray absorptiometry for measuring bone 
mineral density (BMD) and a thoracic and lumbar spine 
radiograph for assessing the presence of asymptomatic 
VFs. In postmenopausal women and men aged 50 years 
and older, osteoporosis and established osteoporosis were 
diagnosed in the presence of T­score <−2.5 and fragility 
fractures, respectively, according to WHO criteria (17). 
In premenopausal women or men less than 50 years of 
age, according to the International Society for Clinical 
Densitometry recommendations, Z­scores were used, 
with Z­scores values of −2.0 or lower considered as low 
BMD for age. Both patients with densitometric diagnosis 
of osteoporosis or low BMD for age and patients with 
VFs regardless of BMD values were included in the 
osteoporotic group.
All patients were screened for PA with aldosterone­
to­renin ratio and in those whose results were positive, 
confirmatory tests were performed according to 
Endocrine Society Guidelines. The presence of a possible 
glucocorticoid remediable aldosteronism (GRA) was ruled 
out by the search for the chimeric gene with the protocol 
previously described (18).
Figure 1
Study design. ST was positive if aldosterone-to-renin ratio 
>300 and plasmatic aldosterone concentration >416 pmol/L. 
SIT was considered positive if plasmatic aldosterone 
concentration >277 pmol/L, negative if plasmatic aldosterone 
concentration <139 pmol/L, indeterminate if 
139 pmol/L > plasmatic aldosterone concentration < 277 pmol/L. 
If SIT was indeterminate, FST was performed. FST was 
considered positive if plasmatic aldosterone concentration 
>166 pmol/L. FST, fludrocortisone suppression test; nPA, not 
primary aldosteronism; OP, osteoporosis; PA, primary 
aldosteronism; ST, screening test; SIT, saline infusion test. 
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In patients with PA, abdomen CT or MRI was asked to 
be performed in order to identify adrenal lesions, possibly 
causing PA.
All subjects gave their witnessed informed consent 
before entering. The study was approved by Ospedale 
Casa Sollievo della Sofferenza, IRCCS and was carried out 
in accordance with the Declaration of Helsinki II.
Methods
In all patients, serum calcium, albumin, phosphorous, 
creatinine, 24­h urinary calcium and creatinine excretion 
were measured by standard colorimetric techniques. Total 
calcium was corrected for serum albumin (Ca alb­adj) 
according to the formula: Ca alb­adj (mg/dL) = total 
calcium + ((4.0 − albumin expressed as g/dL) × 0.8) (19). 
Serum intact parathyroid hormone (PTH) levels were 
measured by an immunochemiluminometric assay (ICMA) 
(LIAISON N­TACT PTH 2 Assay; Diasorin, Stillwater, 
MN, USA), with intra­ and interassay coefficients of 
variation (CVs) of 5.1% and 8.2%, respectively. Serum 
25­hydroxyvitamin D (25OHD) concentration was 
measured by radioimmunoassay (RIA) (Diasorin), whose 
intra and interassay CVs were 7.2% and <12%, respectively. 
In all patients, plasma aldosterone concentration 
(PAC) was measured by RIA (Diasorin), whose intra­ 
and interassay CVs were 3.8% and 7%, respectively. 
Plasma renin activity (PRA) levels were measured by RIA 
(Diasorin), whose intra­ and interassay CVs were 7.5% 
and 8.1%, respectively. Blood samples for the screening 
test, aldosterone­to­renin ratio (ARR), were collected 
at mid­morning, after the patient had been up (sitting, 
standing or walking) for at least two hours and seated for 
five to 15 min (16). The saline infusion test (confirmatory 
test in patients screened positive) was performed while 
the patients were in the recumbent position for at least 
one hour before and during the infusion of two L of 0.9% 
saline i.v. over four hours, starting between 08:00 h and 
09:30 h. Blood samples for PRA, aldosterone, cortisol and 
plasma potassium were drawn at time zero and after four 
hours. If the saline infusion test did not exclude or confirm 
the diagnosis of PA, the fludrocortisone suppression 
test was performed. For the fludrocortisone suppression 
test, patients received 0.1 mg oral fludrocortisone every 
six hours for four days, together with slow­release KCl 
supplements and slow­release NaCl supplements plus 
sufficient dietary salt to maintain a urinary sodium 
excretion rate of at least 3 mmol/kg of body weight. On 
day five, plasma aldosterone and PRA were measured at 
10:00 h with the patient in the seated posture, and plasma 
cortisol was measured at 07:00 h and 10:00 h (16).
BMD was measured by dual­energy X­ray 
absorptiometry (GE Lunar Prodigy, GE Healthcare Lunar) 
at lumbar spine (LS; in vivo precision 1.0%), total hip 
and femoral neck (TN and FN; in vivo precision 2.3% and 
1.8%, respectively). Individual BMD values are expressed 
as s.d. units (Z­values) in relation to our reference age­ 
and gender­matched population (20). Fractured vertebrae 
were excluded from BMD measurement. Conventional 
spinal radiographs in lateral (T4–L4) and anteroposterior 
projection were obtained in all subjects. Two trained 
radiologists who were blinded to BMD and hormonal data, 
independently reviewed the radiographs and evaluated the 
presence of fractures according to the semi­quantitative 
Genant method (21); the interobserver reliability between 
the two radiologists was good (k = 0.82).
There were no patients that received MRA when 
they were doing absorptiometry and urine electrolyte 
measurement.
Statistical analysis
Data are expressed as mean ± s.d. if not differently 
specified. Normality of distribution was evaluated 
by Kolmogorov–Smirnov test. Comparisons between 
continuous or categorical variables were performed by 
unpaired t test or Mann–Whitney U test and by chi­square 
or Fisher exact test respectively, as appropriate. Bivariate 
correlations between continuous variables were performed 
by Pearson correlation or Spearman’s rho correlation, as 
appropriate. In all patients, logistic regression analysis 
was used to assess the association between the presence 
of osteoporosis or fractures as dependent variables and 
age, body mass index (BMI), presence of PA, essential 
hypertension (EH) and spinal BMD (only for fractured 
patients, expressed as Z score) as independent variables; 
we chose such variables because they affect bone mass 
and/or contribute to the development of VFs, apart from 
PA and EH.
The analyses were performed with SPSS 19. A P value 
<0.05 was considered significant.
Results
The clinical characteristics of the whole population 
included are summarized in Table 1.
Of the 322 subjects who took part in the study, 
115 were hypertensive patients and 207 were not, 
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according to the guidelines for the management 
of arterial hypertension of the European Society of 
Cardiology (22).
PA was diagnosed in 11 out of 213 osteoporotic patients 
(5.2%) and 1 out of 109 non osteoporotic subjects (0.9%, 
P = 0.066). The overall prevalence of PA was 3.7% (12/322 
subjects), but it increases to 5.2, 6.9, 9.1 and 9.6%, when 
considering only osteoporotic patients (eleven to 213), 
fractured patients (five to 72), hypercalciuric patients 
(seven to 77) and hypertensive patients (eleven to 115) 
respectively (Fig. 2).
The prevalence of PA among patients that were 
both: osteoporotics and hypertensive was 13.9% (ten 
to 72); fractured and hypertensive was 14.8% (four to 
27); osteoporotics and hypercalciuric was 9.5% (six to 
63); fractured and hypercalciuric was 11.1% (two to 18); 
osteoporotics, hypertensive and hypercalciuric was 26.1% 
(six to 23); fractured, hypertensive and hypercalciuric was 
33.3% (two to six) (Fig. 2).
The clinical features of patients with PA and without 
PA (nPA group) are reported in Table  2. Age and BMI 
were comparable between the two groups. There was one 
premenopausal woman in the PA group and twenty­one 
women in the nPA group; all men were eugonadal.
In PA subjects, as expected, PAC was significantly 
higher, while potassium levels were significantly lower 
than that in the other subjects. In the PA group, there 
was a significant higher systolic blood pressure (SBP) and 
Table 1 Clinical characteristics of all subjects (n = 322) 
enrolled in the study. Data are expressed as mean ± s.d. or 
median (range), as appropriate. The prevalence and 
percentage of hypertension, hypercalciuria, vertebral fractures 
and osteoporosis are reported.
Characteristics Values
Age (years) 61.1 ± 9.5
BMI (kg/m2) 25.5 (30.6)
PAC (pmol/L) 128 (559)
SBP (mmHg) 120 (100)
DBP (mmHg) 76 (55)
K+ (mEq/L) 4.31 ± 0.38
Serum calcium albumin adjusted (mmol/L) 2.24 ± 1.01
Phosphorous (mmol/L) 1.10 ± 0.15
Creatinine (µmol/L) 62.9 ± 12.4
PTH (pmol/L) 5.4 (15.2)
25OH_VitD (nmol/L) 44.9 (187.5)
Urinary calcium (mmol/day) 4.9 ± 2.6
uCa/kg (µmol 24 h/kg) 78 ± 40
BMD_LS (Z score) −0.94 ± 1.25
BMD_FN (Z score) −0.61 ± 0.89
BMD_TN (Z score) −0.50 ± 1.00
Hypertension, n (%) 115 (35.7)
Osteoporosis, n (%) 213 (66.1)
Vertebral fractures, n (%) 72 (22.4)
Hypercalciuria, n (%) 77 (23.9)
Primary aldosteronism, n (%) 12 (3.7)
DBP, diastolic blood pressure; PAC, plasma aldosterone concentration; 
SBP, systolic blood pressure; uCa/kg, urinary calcium in a day/kg (weight).
Figure 2
Prevalence of primary aldosteronism. OP, osteoporosis; Fx, 
vertebral fracture. *P < 0.05; ^P < 0.01; #P < 0.001 in respect to 
the subjects without features reported in the column.
Table 2 Clinical characteristics of subjects with and without 
PA enrolled in the study. Data are expressed as mean ± s.d. or 
median (range), as appropriate. The prevalence and 
percentage of hypertension, hypercalciuria, vertebral fractures 
and osteoporosis are reported.
 nPA (n = 310) PA (n = 12)
Age (years) 61.1 ± 9.3 60.4 ± 13.5
BMI (kg/m2) 25.6 (30.6) 23.9 (21)
PAC (pmol/L) 126 (539) 243 (420)a
SBP (mmHg) 120 (95) 140 (90)a
DBP (mmHg) 75 (55) 83 (35)b
K+ (mEq/L) 4.33 ± 0.38 3.97 ± 0.34a
Serum calcium albumin 
adjusted (mmol/L)
2.24 ± 0.10 2.23 ± 0.13
Phosphorous (mmol/L) 1.11 ± 0.15 1.01 ± 0.10c
Creatinine (µmol/L) 62.8 ± 12.4 61.9 ± 11.5
PTH (pmol/L) 5.4 (14.2) 7.3 (14.7)b
25OH_VitD (nmol/L) 45 (188) 29 (123)
Urinary calcium (mmol/day) 4.8 ± 2.5 7.6 ± 3.2a
uCa/kg (µmol 24 h/kg) 75 ± 40 113 ± 35a
BMD_LS (Z score) −0.95 ± 1.25 −0.70 ± 1.25
BMD_FN (Z score) −0.61 ± 0.89 −0.68 ± 0.78
BMD_TN (Z score) −0.51 ± 1.00 −0.26 ± 1.03
Hypertension, n (%) 104 (33.5) 11 (91.7)a
Osteoporosis, n (%) 202 (65.2) 11 (91.7)
Vertebral fractures, n (%) 67 (21.6) 5 (41.7)
Hypercalciuria, n (%) 70 (22.6) 7 (58.3)b
aP < 0.001 vs nPA; bP < 0.01 vs nPA; cP < 0.05 vs nPA.
DBP, diastolic blood pressure; nPA, not primary aldosteronism; PA, 
primary aldosteronism; PAC, plasma aldosterone concentration; SBP, 
systolic blood pressure; uCa/kg, urinary calcium in a day/kg (body weight).
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diastolic blood pressure (DBP) as well as there was a higher 
prevalence of hypertensive patients (Table 2).
In the twelve patients, with PA there was a 
significantly higher urinary calcium excretion as well as 
a higher prevalence of hypercalciuric patients (i.e. uCa 
>100 µmol/kg body weight/day) (23) than in the other 
subjects. Moreover, serum PTH levels were significantly 
higher, while serum phosphorous levels were lower in PA 
than those in nPA group (Table 2).
In the whole sample, there was a weak but significant 
direct association between serum aldosterone and 
daily urinary calcium excretion (r = 0.123, P = 0.028) or 
urinary calcium/weight ratio (µmol Ca/kg body weight) 
(r = 0.124, P = 0.027). Furthermore, there was a significant 
direct association between serum aldosterone and PTH 
(r = 0.160, P = 0.005).
Logistic regression analysis showed that (i) osteo­
porosis was significantly associated with age (OR 1.06, 
CI 1.03–1.09, P = 0.001), BMI (OR 1.11, CI 1.05–1.17, 
P = 0.001) and PA (OR 10.42, CI 1.21–90.91, P = 0.033), but 
not with presence of EH (OR 1.23, CI 0.72–2.10, P = 0.46); 
(ii) fractures were significantly associated with age (OR 
1.06, CI 1.03–1.10, P = 0.001) and spinal BMD (OR 1.71, 
CI 1.30–2.25, P = 0.001), but not with the presence of PA 
(OR 3.22, CI 0.90–12.20, P = 0.071) and of EH (OR 1.02, 
CI 0.55–1.89, P = 0.95).
In ten out of the 12 PA patients, abdomen CT or MRI 
was performed, while two patients refused to perform 
imaging studies. In three patients, a unilateral nodular 
adrenal lesion was detected while in five patients bilateral 
or monolateral adrenal hypertrophy was found. Imaging 
studies were negative in the remaining two patients. 
None of the patients agreed to undergo surgery; therefore, 
adrenal veins catheterization was not performed (16).
Discussion
The present study suggests the role of aldosteronism 
as a secondary cause of osteoporosis. Indeed, we found 
a 5.2% prevalence of aldosteronism among patients 
with osteoporosis and 6.9% in those with fractures, 
after exclusion of secondary causes of osteoporosis (24) 
apart from hypercalciuria, according to our protocol 
(15). Interestingly, our data showed that about a 
quarter of patients with osteoporosis, hypertension and 
hypercalciuria were affected with PA, thus providing for 
the first time the clinical features of a typical patient with 
primary hyperaldosteronism and coexistent osteoporosis.
Aldosteronism has been associated with cardiovascular 
and renal injury (inflammation, remodeling and fibrosis) 
(25) and more recently with bone damage (4, 5, 6, 7, 8, 9). 
In an animal model, as well as in humans, aldosterone 
excess was associated with an increased urinary and fecal 
loss of Ca++ and Mg++, in turn inducing hypocalcemia, 
hypomagnesemia and secondary hyperparathyroidism 
(1, 2, 3, 4, 5, 6), that was rescued by adrenalectomy or 
treatment with MRA (4, 5). These alterations seem to lead 
to low bone mass and fragility fractures, whereas surgery or 
MRA improved bone mass (4, 5). Moreover, spironolactone 
reduced fracture risk in men with congestive heart failure 
(26). For these reasons, we decided to search for an excess 
of mineralocorticoids in consecutively recruited patients 
with osteoporosis.
The direct associations we found between serum 
aldosterone and urinary calcium excretion and between 
serum aldosterone and PTH confirm the effect of 
aldosteronism on renal calcium handling, resulting in 
hypercalciuria and consequent hyperparathyroidism. 
Although it is well known that hypercalciuria and 
secondary hyperparathyroidism can cause osteoporosis 
(27), we believe that they do not fully explain the 
high prevalence of PA patients we observed among 
osteoporotic or fractured subjects (5.2% and 6.9% 
respectively). It is interesting to note that the recent 
genome wide association study, aimed at identifying 
new candidate genes for bone strength, showed a strong 
association between phenotypes of bone strength and 
genes belonging to the mineralocorticoid pathway (10). 
In this regard, it should be mentioned that the expression 
of mineralocorticoid receptors on bone cells (11, 12) 
could actually suggest a still unknown direct effect of 
mineralocorticoids on the skeletal tissue. Indeed, in an 
animal model, Fumoto et al. showed that pharmacological 
inhibition of mineralocorticoid function with eplerenone 
resulted in increased bone mass, with stimulation of 
bone formation and suppression of resorption (12). The 
treatment with eplerenone as well as the specific deletion 
of mineralocorticoid receptor in osteocytes improved 
the cortical bone thinning in the prednisolone­treated 
mouse (12).
The presence of PA in patients with osteoporosis and/
or fragility fracture, in the absence of a picture of severe 
hypertension as commonly believed in PA patients, is 
not completely unexpected, since a high prevalence of 
aldosteronism among normotensive patients has been 
reported (28, 29).
In our report, we excluded hypertensive patients 
whether we could not change antihypertensive therapy 
with verapamil and doxazosin; thus, we could have not 
identified some hypertensive patients with PA. Therefore, 
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in these patients, we suspect that the prevalence of 
aldosteronism could be even higher. Consequently, the 
prevalence of PA patients in osteoporosis should be higher 
than we actually observed.
Our study has several limitations. Firstly, its cross­
sectional design shows association and not causality. 
Intervention studies should be planned to evaluate the 
effect of surgical or pharmacological treatment on bone 
mass and incidence of fractures in patients with PA. This 
study due to the assumption of antihypertensive drugs 
and/or drugs for the treatment of osteoporosis, can result 
in a selection bias since more than two thousand subjects 
were excluded from the analysis and this could have 
affected the true prevalence of PA among patients with 
osteoporosis. The studied sample size is relatively small 
due to exclusion criteria above described. Nevertheless, 
our findings are fairly coherent, and in keeping with 
data from animal models and patients treated with 
spironolactone.
Notwithstanding these limitations, the study has 
an important clinical implication. Indeed, it suggests 
PA is a cause of osteoporosis and should be searched for 
in patients with an unexplained form of osteoporosis, 
particularly in hypertensive subjects with hypercalciuria.
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